Clinical Trial Update: Double-blind, Randomized, Vehicle- and Comparator-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of LAS41007 in the Treatment of Actinic Keratosis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the efficacy and safety of LAS41007 for actinic keratosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• LAS41007

Snippet

Sponsor: Almirall, S.A. | Conditions: Actinic Keratosis | Phase 3 | Status: COMPLETED